MYC and lymphoma: For example, S63845 showed synergy with current therapies in preclinical models of two types of breast cancer.116 Importantly, mice tolerated S63845 well, with normal tissues unaffected at doses that eradicated MYC-driven mouse lymphomas.115 Thus, a therapeutic window seems likely.